more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$484.47 USD

+12.12 (2.57%)

Updated Sep 9, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

Top 28% (70 out of 249)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

by Zacks Equity Research Published on February 08,2022

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research Published on February 02,2022

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Idexx Laboratories (IDXX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on February 02,2022

Idexx (IDXX) delivered earnings and revenue surprises of 13.17% and 2.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN

by Debanjana Dey Published on February 01,2022

The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 27,2022

Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.

Analysts Estimate Idexx Laboratories (IDXX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on January 26,2022

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDXXPositive Net Change

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research Published on January 20,2022

Style Box ETF report for IWP

IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test

by Zacks Equity Research Published on January 17,2022

Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.

IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth

by Zacks Equity Research Published on January 11,2022

Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.

medical-devices

Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?

by Zacks Equity Research Published on January 10,2022

Style Box ETF report for IWR

Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know

by Zacks Equity Research Published on December 30,2021

Idexx Laboratories (IDXX) closed at $661.32 in the latest trading session, marking a +0.86% move from the prior day.

IDXXPositive Net Change

IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline

by Zacks Equity Research Published on December 28,2021

IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.